We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Largest Reorg in FDA History Featured in Califf Senate Budget Testimony

Largest Reorg in FDA History Featured in Califf Senate Budget Testimony

May 10, 2024

A major agency-wide reorganization affecting regulatory affairs and medical products, and more than $12 million to tackle supply chain issues across all products areas, were included in the FDA’s FY 2025 budget proposed to a Senate Appropriations subcommittee Wednesday morning by Commissioner Robert Califf.

Addressing the Subcommittee of Agriculture, Rural Development, Food and Drug Administration and Related Agencies, Califf outlined what he labeled the FDA’s largest reorg in its history that will impact nearly half of the agency’s 18,000 employees.

Califf highlighted the agency’s priority of aggressively tackling drug and device shortages while acknowledging factors beyond its control, including manufacturing issues and delays, market failures and discontinuations. He is seeking $12.3 million to enhance the FDA’s capabilities in making supply chains more resilient, increase regulatory oversight and mitigate shortages of critical medical and food products.

View the Subcommittee hearing here.

To read the whole story, click here.

Related Topics

Drugs Devices Regulatory Affairs Regulatory Affairs

    Upcoming Events

    • 14May

      2024 Avoca Quality Consortium Summit

    • 23May

      Maximizing Trial Success Requires Evolving Feasibility and Recruitment Strategies

    • 30May

      FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule

    • 20Jun

      Inspection Readiness for EU GMP Annex 1 – Manufacture of Sterile Medicinal Products

    • 21Oct

      MAGI@home Clinical Research Conference 2024

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Largest Reorg in FDA History Featured in Califf Senate Budget Testimony

    • Removal of Heparin Coating on Tubing Earns Bioptimal FDA Warning Letter

    • FDA, USDA and EPA to Coordinate on Biotechnology Products

    • Software Glitch Brings Class I Recall of Mobile App for Insulin Pump

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing